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Crataegus monogyna is mainly used in the treatment of cardiac and circulatory system 
disorders. In vitro and clinical studies are indicative of the fact that the hydroethanolic extract 
of C. monogyna has angiotensin converting enzyme (ACE) inhibitory activity. This study 
sought to support these claims through the use of in silico modelling techniques. Possible 
binding conformations for β-amyrin, oleanolic acid and ursolic acid were generated using 
captopril, as well as enalaprilat and lisinopril, as template ligands. The ligand binding affinity 
(LBA) of each was calculated and the best binding conformation of each triterpene was 
established. Results indicate that these naturally occuring terpenes possess in silico 
predicted ligand binding affinities that are superior to both the small molecule captopril and 
the larger molecules enalaprilat and lisinopril. 
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INTRODUCTION 
  
Hypertension is recognised as being one of the most 
preventable causes of premature morbidity and mortality. 
The World Health Organization (WHO) statistics indicate 
that hypertension affects approximately 40% of all 
individuals aged 25 years and over. It is prevalent 
worldwide in both developed and developing countries 
(WHO, 2012). The majority of hypertensive patients cur-
rently rely on the use of angiotensin converting enzyme 
(ACE) inhibitors for management of their condition 
(Sweileh et al., 2009). 
In silico models are of value in that they allow virtual 
screening for desirable properties and further optimization       
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optimization of identified lead candidate molecules, thus 
drastically lowering financial and time requirements for 
the chemical synthesis and biological testing of promising 
leads. They also minimise animal testing; a factor that 
should not be considered superficial in the highly 
regulated and ethically conscious scenario in which 
contemporary drug discovery operates (Kapetanovic, 
2008). 
In vitro and clinical studies have indicated that the 
triterpenic extract of Crataegus monogyna is capable of 
exerting an inhibitory effect on the ACE (Attard and 
Attard, 2006). Subsequent to this work, we hereby report 
the results of a static in silico investigation of the ACE 
and of the molecular and conformational bases for the 
ACE inhibitory effect exerted by the terpenoid extract of 
C. monogyna, which to our knowledge has as yet not 
been described. 
  
 
 
 
 
MATERIALS AND METHODS 
 
Protein data bank (PDB) deposition selection 
 
Three Protein data bank (Bernstein et al., 1977) depositions were 
selected as templates for this study. These were PDB IDs 1UZF 
(Natesh et al., 2004), 1UZE (Natesh et al., 2004) and 1O86 (Natesh 
et al., 2003), describing the bound co-ordinates of testicular ACE 
and the small molecules captopril (resolution 2.00 Ǻ), enalaprilat 
(resolution 1.82 Ǻ) and lisinopril (resolution 2.00 Ǻ). 
 
 
PDB deposition visualisation and modelling 
 
Molecular visualisation and modelling were carried out using 
SYBYL
®
 (SYBYL 7.3, Tripos International, 1699 South Hanley Rd., 
St. Louis, Missouri, 63144, USA.) (SYBYL 7.3, Tripos International, 
Cartera™). The selected PDB depositions were treated identically 
during this phase of the study. Specifically, each crystallographic 
deposition 1UZF, 1UZE and 1O86 was read into SYBYL
®
 (SYBYL 
7.3, Tripos International, Cartera™) with precautions being taken to 
preserve the bound co-ordinates and consequently the bioactive 
conformation of each. All moeities considered as superfluous to 
binding were edited. This means that in the case of 1UZF, two 
chlorine atoms, 2 N-acetylglucosamine molecules and all water 
molecules lying at a distance ≤ 5 Å were removed. In the cases of 
1UZE and 1O86, two chlorine atoms and two glycine molecules 
were removed. The result of this editing process consequently was 
holo-ACE bound to captopril, enalaprilat and lisinopril, respectively 
with water molecules at a radius ≤ 5 Å being retained.  
Retention of these water molecules was carried out on the 
premise that crystallographic data was suggestive of the fact that 
their proximity to the bound small molecules and the ligand binding 
pocket (LBP) could give rise to a situation in which bound ligands 
could be stabilised within the LBP through the formation of water 
bridges. This editing process was performed in preparation for 
molecular dynamics studies which will be carried out during 
subsequent stages of this study. 
The small molecules captopril, enalaprilat and lisinopril were 
subsequently extracted, using SYBYL
®
 (SYBYL 7.3, Tripos 
International, Cartera™), from their respective ACE ligand binding 
pockets (ACE-LBP). Each small molecule was saved in PDB and 
mol2 formats while the apo-ACE with the retained water molecules 
(n = 143, 455 and 569, respectively) were saved in pdb format. The 
choice of file format in which to save each moeity was a function of 
software requirements of subsequent phases of the study. 
Specifically, ligand binding affinity (LBA) and de novo design were 
carried out using the algorithms of Wang and co-workers in 
SCORE
®
 (Wang et al., 1998) and LigBuilder® (Wang et al., 2000), 
respectively. These require that small molecules be saved in mol2 
format and that the protein receptor be saved in pdb format. VMD® 
(Humphrey et al., 1996) was used for image generation and this 
required that all molecules be read in pdb format. 
 
 
Analysis of the ligand binding pocket 
 
The extracted bioactive conformations of the small molecules 
captopril, enalaprilat and lisinopril were used as probes in order to 
generate ACE-LBP maps of each bound conformation of the ACE. 
This was done using the pocket module of LigBuilder ® (Wang et 
al., 2000) which exploited the contacts forged between the small 
molecule and the ACE-LBP in each case to generate a 3D bond 
type specific map of the ACE-LBP as described in each deposition 
being    studied.    This      process      also     generated   proposed  
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pharmacophores for each deposition. Elucidation of ligand specific 
LBP maps and pharmacophores was carried out based on the fact 
that it is known that receptor tertiary structure and LBP 
conformation is specific ligand driven. This process consequently 
served to highlight the conformational differences that the 3 ligand 
probes induced within the ACE-LBP. At the end of this process, 
consequently, 2 output files were generated for each deposition. 
These were: 
 
1. The key_site_file depicting the key interaction sites between the 
amino acid side chains lining the ACE-LBP and the resident small 
molecule. By convention, hydrogen bond donor sites were 
represented in blue, hydrogen acceptor sites were represented in 
red, while hydrophobic sites were represented in cyan. 
2. The pharmacophore_file depicting the proposed pharmacophoric 
model. Colour conventions were assigned in the same manner as 
described for the key_site_file. 
 
Both files were saved in pdb format such that they could be later 
used in the visualization software VMD® (Humphrey et al., 1996). 
 
 
Estimation of the ligand binding affinity (LBA) of the template 
ligands for the ACE receptor 
 
The apo-ACE files which were generated when the selected pdb 
depositions were edited together, with their respective extracted 
small molecules saved in mol2 format, which were read into and 
processed in SCORE
®
 (Wang et al., 1998). Through its static 
algorithm, the in silico provided LBA (pKd) of each of the small 
molecules captopril, enalaprilat and lisinopril and was calculated for 
the respective cognate receptor. 
 
 
Superimposition of the triterpene molecules onto the bound 
coordinates and 3D volume of the template ligands 
  
In this part of the study, the bioactive conformations of the small 
molecules captopril, enalaprilat and lisinopril together with the 3D 
volumes which they occupy within their respective ACE-LBP 
conformations were used to guide β-amyrin, oleanolic acid and 
ursolic acid, all of which are constituents of C. monogyna, into the 3 
conformations of the ACE-LBP. This was done in order to identify 
the highest affinity conformers for each molecule, and to utilise 
these during subsequent stages of the rational drug design 
process. Identification of the optimally binding conformations of the 
triterpenic small molecules was carried out using the Similarity Suite 
algorithm in SYBYL
®
 (SYBYL 7.3, Tripos International, Cartera™). 
This algorithm facilitated initial positioning of each small molecule 
within the ACE-LBP based on the conformation of its cognate 
ligand. Subsequent to this process the triterpenic molecules were 
allowed conformational rotation within each ACE-LBP conformation. 
The 21 conformers for each molecule which exhibited optimal 
binding characteristics were selected and their in silico LBA (pKd) 
was then quantified in SCORE
®
 (Wang et al., 1998). 
 
 
RESULTS  
 
The in silico LBA (pKd) of captopril, enalaprilat and 
lisinopril for their cognate receptor was predicted to be 
5.36, 6.44 and 6.53, respectively. Significant differences 
in ACE-LBP occupation by captopril, enalaprilat and 
lisinopril could be seen when the LBP maps generated by  
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Table 1. The LBA (pKd) of the 21 optimally binding conformers of each terpene ligand based on the three different template 
ligands employed in this study as calculated in SCORE
®
. 
 
Captopril  Enalaprilat  Lisinopril 
β-amyrin 
Oleanolic 
acid 
Ursolic 
acid 
 
 
β-amyrin 
Oleanolic 
acid 
Ursolic 
acid 
 
 
β-amyrin 
Oleanolic 
acid 
Ursolic 
acid 
6.56 6.95 6.74  7.03 7.04 7.26  6.98 6.78 7.37 
6.56 6.95 6.74  7.00 7.13 7.23  7.05 6.66 7.34 
6.30 7.04 6.82  7.24 7.14 7.35  6.81 7.19 7.41 
6.55 6.62 6.68  7.10 7.21 7.21  7.09 6.93 6.95 
6.56 6.70 6.69  7.04 7.17 7.15  7.11 6.94 6.85 
6.62 6.64 7.18  7.15 7.13 7.59  7.00 7.00 6.96 
6.74 6.68 7.14  7.18 7.20 7.29  6.64 7.04 7.02 
6.63 6.94 6.53  7.03 7.20 7.19  6.89 6.99 7.30 
6.60 6.99 6.94  6.94 7.19 7.36  6.62 6.89 7.34 
7.25 6.53 7.27  7.30 7.41 7.25  6.53 7.35 6.85 
6.57 6.94 7.30  7.25 7.05 7.31  7.25 6.59 7.27 
6.67 6.89 7.24  7.20 7.42 6.93  6.88 6.87 7.08 
6.61 6.64 7.29  7.20 7.43 7.42  6.89 6.90 7.05 
6.64 6.69 7.69  6.69 7.44 7.43  6.94 6.90 7.17 
6.56 6.98 7.84  6.67 7.46 7.26  6.94 6.52 7.07 
6.47 6.36 7.11  6.68 7.25 7.08  6.55 6.52 6.62 
6.47 6.94 7.79  6.77 7.29 7.21  6.74 6.37 6.81 
6.47 6.47 7.15  7.05 7.11 7.20  6.39 6.73 6.63 
6.82 6.61 7.41  6.80 7.02 6.67  6.68 6.74 6.80 
6.86 6.17 6.76  6.77 7.05 6.58  6.74 6.11 6.55 
6.56 6.95 6.83  7.03 7.04 7.26  6.98 6.78 7.37 
  
 
 
 
 
Figure 1. Key interaction sites of captopril (in 
orange), enalaprilat (in green) and lisinopril (in 
blue) rendered in VMD
®
. 
 
 
each molecule were compared (Figure 1). Similarly, the 
proposed pharmacophores in each case were also 
dissimilar (Figure 2). The LBAs of the 21 optimally 
binding conformers of β-amyrin, oleanolic acid and ursolic 
acid for the captopril-, enalaprilat- and lisinopril- bound 
conformations of the ACE were calculated and are shown 
in Table 1. The most salient finding in this case was that 
the   predicted   in  silico   LBAs   of    all  3  experimental  
 
 
Figure 2. Proposed pharmacophores of captopril 
(in orange), enalaprilat (in green)  and lisinopril  
(in blue) rendered in VMD
®
. 
 
 
triterpenes (pKd 7.25, 7.46 and 7.84) exceeded those 
calculated for captopril, enalaprilat and lisinopril (pKd 
5.36, 6.44 and 6.53, respectively). 
 
 
DISCUSSION 
 
This in silico study further corroborates the hypothesis  
  
 
 
 
 
of Attard and Attard (2006) that the triterpenic extract of 
C. monogyna has ACE inhibitory activity. All three 
molecules β-amyrin, oleanolic acid and ursolic acid 
exhibit binding affinities (7.25, 7.46 and 7.84, 
respectively) that are superior to those of captopril, 
enalaprilat and lisinopril (5.36. 6.44 and 6.53, 
respectively), implying a superior inhibitory activity when 
compared to the ACE inhibitors that are currently in 
widespread clinical use. Although this study utilised 
algorithms that were static, it was still possible to infer the 
importance of understanding the dynamic nature of both 
the ACE and its cognate small molecules. This is borne 
out by the fact that ACE-LBP maps and proposed 
pharmacophores were obtained that differed according to 
resident ligand. This was indicative of the fact that LBP 
conformation is essentially ligand driven. The fact that for 
example, ursolic acid had a LBA which was highest when 
captopril was used as a template may be taken to imply 
that ursolic acid adopts a captopril-like conformation 
within the ACE-LBP. A similar conclusion may be drawn 
for oleanolic acid whose best LBA was observed when its 
conformation within the ACE-LBP was modelled on that 
of enalaprilat. It was also interesting to note that in the 
case of β-amyrin, the in silico calculated LBA for its 
optimally binding conformation remained constant 
irrespective of which ACE inhibitor it was modelled on. 
This conformation of β-amyrin is consequently very 
interesting from a rational drug design point of view.  
The results obtained from this study consequently open 
new avenues for the rational design of ACE inhibitors 
based on the triterpenic scaffold. A molecular dynamics 
simulation through which the dynamic interactions 
between the ACE and the ACE inhibitors captopril, 
enalaprilat and lisinopril may be compared with those 
between the ACE and the triterpenic molecules β-amyrin, 
oleanolic acid and ursolic acid represents the next step in 
this direction. 
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